Research
Hormonal
Incretin agonist therapies improve type 2 diabetes outcomes and cardiovascular mortality.
Incretin agonists may be a viable alternative to surgery for managing diabetes and cardiovascular risks.
StrongSupportsmedium confidence
As for bariatric surgery, incretin agonist therapies also improve type 2 diabetes outcomes, cardiovascular mortality and other obesity-related complications.
Why this rating
The claim is based on emerging evidence and ongoing studies.
Source
Treatment of obesity: will incretin agonists make bariatric surgery a thing of the past?
Siehoon Lah et al. · Internal Medicine Journal · 2025
reviewCited 3×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →